Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-BIO-1819578
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
11C-BIO-1819578 (also known as [11C]BIO-1819578) is a carbon-11 labeled positron emission tomography (PET) radioligand developed by Biogen in collaboration with Karolinska Institutet and Sentonix. It is designed to target and image O-GlcNAcase (OGA) in the living brain. OGA is an enzyme that catalyzes the removal of O-linked β-N-acetylglucosamine (O-GlcNAc) modifications from proteins, and its inhibition is a therapeutic strategy to prevent the aggregation of hyperphosphorylated tau protein in neurodegenerative diseases such as Alzheimer's disease. 11C-BIO-1819578 is utilized as a diagnostic imaging tool to evaluate target engagement and determine brain OGA occupancy of therapeutic OGA inhibitors, such as Biogen's BIIB113, in clinical trials.
- Other names
- (S)-N-(5-((3-((5-fluoropyridin-2-yl)(methyl)amino)piperidin-1-yl)methyl)thiazol-2-yl)acetamide[11C]BIO-1819578BIO1819578BIO-1819578BIO 1819578
02
Targets
OGA (Protein O-GlcNAcase)
Beyond the preview
Go deeper on 11C-BIO-1819578.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-BIO-1819578.